Literature DB >> 1419118

Immunogenicity and toxicity of lipopolysaccharide from Francisella tularensis LVS.

G Sandström1, A Sjöstedt, T Johansson, K Kuoppa, J C Williams.   

Abstract

Lipopolysaccharide (LPS) from the live vaccine strain of Francisella tularensis (F. tularensis LVS) was isolated and purified. The LPS did not stimulate lymphocytes from previously tularaemia-vaccinated individuals or lymphocytes from non-primed individuals. However, serum antibodies from tularaemia vaccinees reacted with the LPS whereas virtually no reactivity was found with antibodies from individuals not exposed to F. tularensis LVS. Antibodies of immunoglobulin class M displayed the antibody reactivity predominantly. The LPS failed to induce the mononuclear cell-derived cytokine interleukin-1 and only low levels of tumour necrosis factor were detected. Furthermore, no LPS endotoxin properties were found in galactosamine-treated mice or in the Limulus amoebocyte lysate assay. From these results it can be concluded that F. tularensis LVS possesses a lipopolysaccharide-like molecule, which does not exhibit properties of a classical endotoxin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419118     DOI: 10.1111/j.1574-6968.1992.tb05902.x

Source DB:  PubMed          Journal:  FEMS Microbiol Immunol        ISSN: 0920-8534


  51 in total

1.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS.

Authors:  Jannet Katz; Ping Zhang; Michael Martin; Stefanie N Vogel; Suzanne M Michalek
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

Review 3.  A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide.

Authors:  Yunhao Tan; Jonathan C Kagan
Journal:  Mol Cell       Date:  2014-04-24       Impact factor: 17.970

4.  Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112.

Authors:  Joshua D Hall; Matthew D Woolard; Bronwyn M Gunn; Robin R Craven; Sharon Taft-Benz; Jeffrey A Frelinger; Thomas H Kawula
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

5.  Novel modification of lipid A of Francisella tularensis.

Authors:  Nancy J Phillips; Birgit Schilling; Molly K McLendon; Michael A Apicella; Bradford W Gibson
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

6.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

7.  Presence of pili on the surface of Francisella tularensis.

Authors:  Horacio Gil; Jorge L Benach; David G Thanassi
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

Review 8.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

9.  Type IV pili in Francisella tularensis: roles of pilF and pilT in fiber assembly, host cell adherence, and virulence.

Authors:  Subhra Chakraborty; Michael Monfett; Tamara M Maier; Jorge L Benach; Dara W Frank; David G Thanassi
Journal:  Infect Immun       Date:  2008-04-21       Impact factor: 3.441

10.  TLR-dependent control of Francisella tularensis infection and host inflammatory responses.

Authors:  Allison L Abplanalp; Ian R Morris; Bijaya K Parida; Judy M Teale; Michael T Berton
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.